Toshihisa Satta, MD, PhD
We post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Areas of Expertise
Conditions I Treat
- Leukemia
- Lymphoma
- Multiple myeloma and other plasma-cell diseases
My Specialties
- Cellular therapy
Get to Know Me
I’m a medical oncologist who is board-certified in hematology and medical oncology. I’m an expert in both hematological malignancies (blood cancers) and solid tumors.
I care for people who are admitted to Memorial Hospital for cellular immunotherapy, or need help with complications (problems) during cancer treatment.
I have a passion for advancing cancer treatments through clinical and laboratory research. I do translational research projects, research aimed at improving treatment outcomes (results) for people having cellular immunotherapy.
When I’m not at the hospital, I have an active lifestyle that helps me balance the demands of being a doctor. I love running, and I am training to complete a full marathon in under 4 hours. Running keeps my body fit. But it also rejuvenates me and restores a clear mind, helping me in my roles as a doctor and researcher.
A cellular therapy specialist is a doctor with special training in using cell therapies to treat health conditions such as cancer. Therapies can include chimeric antigen receptor (CAR) T cell therapy.
I'm a hematologist-oncologist, which is a doctor who treats cancers of the blood. A hematologist (HEE-muh-TAH-loh-jist) diagnoses and treats blood disorders. An oncologist is a cancer doctor.
- Assistant Attending Physician
Conditions I Treat
- Leukemia
- Lymphoma
- Multiple myeloma and other plasma-cell diseases
- Melanoma
My Specialties
- Cellular therapy
Education
- MD, Tokyo Medical and Dental University
- PhD, Tokyo Medical and Dental University
Residencies
- Internal Medicine, Mount Sinai Beth Israel
Fellowships
- Hematology and Medical Oncology, Virginia Commonwealth University
- Adult Bone Marrow Transplantation, Memorial Sloan Kettering Cancer Center
Board Certifications
- Hematology
- Medical Oncology
- Internal Medicine
Awards and Honors
- Rising Scholar, Virginia Commonwealth University (2020-2022)
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
HMO, EPO PPO, POS, Transplant
In Network Coverage Type
PPO
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
Supplemental
In Network Coverage Type
PPO, POS, HMO
In Network Coverage Type
POS, EPO, HMO
In Network Coverage Type
PPO, POS, EPO, HMO
Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.
In Network Coverage Type
HMO
In Network Coverage Type
PPO, HMO
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
HMO, EPO
Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.
In Network Coverage Type
HMO
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
EPO, HMO, PPO, POS
Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.
In Network Coverage Type
HMO
In Network Coverage Type
HMO, PPO
In Network Coverage Type
PPO EPO
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
PPO, HMO
In Network Coverage Type
State Government
In Network Coverage Type
PPO, POS, EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
HMO
City Employee Health Plans (Gold and Gold Care)
In Network Coverage Type
Supplemental
In Network Coverage Type
PPO/OAP
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
TBD
In Network Coverage Type
HMO/EPO
In Network Coverage Type
PPO, EPO
In Network Coverage Type
PPO, POS, HMO
In Network Coverage Type
State Government
In Network Coverage Type
State Government
In Network Coverage Type
PPO, HMO
In Network Coverage Type
PPO, POS
In Network Coverage Type
PPO, POS, HMO
In Network Coverage Type
State Government
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Contact and Location
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Satta T, Li L, Chalasani SL, Hu X, Nkwocha J, Sharma K, Kmieciak M, Rahmani M, Zhou L, Grant S. Dual mTORC1/2 Inhibition Synergistically Enhances AML Cell Death in Combination with the BCL2 Antagonist Venetoclax. Clin Cancer Res. 2023 Apr 3;29(7):1332-1343. doi: 10.1158/1078-0432.CCR-22-2729. PMID: 36652560; PMCID: PMC10073266.
Satta T, Grant S. Enhancing venetoclax activity in hematological malignancies. Expert Opin Investig Drugs. 2020 Jul;29(7):697-708. doi: 10.1080/13543784.2020.1789588. Epub 2020 Jul 16. PMID: 32600066; PMCID: PMC7529910.
Simmons GL, Satta T, Castaneda Puglianini O. Clinical experience of CAR T cells for multiple myeloma. Best Pract Res Clin Haematol. 2021 Sep;34(3):101306. doi: 10.1016/j.beha.2021.101306. Epub 2021 Aug 28. PMID: 34625232.
Visit PubMed for a full listing of Dr. Satta’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Members of the MSK Community often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community. These activities outside of MSK further our mission, provide productive collaborations, and promote the practical application of scientific discoveries.
MSK requires doctors, faculty members, and leaders to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public. Not all disclosed interests and relationships present conflicts of interest. MSK reviews all disclosed interests and relationships to assess whether a conflict of interest exists and whether formal COI management is needed.
Toshihisa Satta discloses the following relationships and financial interests:
-
Aptitude Health
Professional Services and Activities
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2024 through disclosure submission in spring 2025). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].